TNFRSF4 and neoplasm: A study that investigated the in situ immunization against both B cell (A20) and T cell (EL4) lymphoma tumor models with PLGA particles co-encapsulating DOX and CpG-ODN showed that the combination regimen was effective at generating systemic responses and reducing tumor burden, which was further enhanced by anti-OX40/anti-CTLA4 monoclonal antibody (mAb) therapies to improve T cell activation and overcome immunosuppression 254.